QualityStocks would like to highlight MGC Diagnostics (NASDAQ: MGCD). The company, previously Angeion Corporation, acquired Medical Graphics Corporation in December 1999. Medical Graphics develops, manufactures and markets non-invasive cardiorespiratory diagnostic systems that are sold under the MedGraphics (www.medgraphics.com) and New Leaf (www.newleaffitness.com) brand names. These cardiorespiratory product lines provide solutions for disease detection, integrated care, and wellness across the entire spectrum of health – whether managing chronic illness, promoting fitness, or training for the Olympics.
In the company’s news,
MGC Diagnostics announced that its new trading symbol, “MGCD,” became effective. In connection with a recent name change, the company’s common stock has been assigned a new CUSIP number, 552768103. Outstanding stock certificates have not been affected by the name change and do not need to be exchanged.
MGC Diagnostics has launched a new corporate Web site and logo as part of a company-wide rebranding initiative. The new identity is intended to better communicate to customers and shareholders what the company brings to the market: leading-edge cardiorespiratory diagnostic technology, a renewed dedication to product innovation, customer service and support that are unmatched, and an aim at anticipating and solving unmet needs. The three vertical elements in the company’s new logo represent MGC Diagnostics’ pillars of commitment: Provide unmatched service and support; relentlessly make improvements; and anticipate and solve unmet customer needs. The circle around the pillars represents the company’s market, as MGC Diagnostics considers everyone who interacts with, uses, or benefits from the company’s products to be a customer.
Designing a differentiated position in the minds of stakeholders, customers, and competitors has been a guiding element of MGC Diagnostics’ strategy. The company has historically operated with three separate identities: Angeion for the investment community, New Leaf in the fitness business, and MEDGRAPHICS in the cardiorespiratory business. Of the three entities, MEDGRAPHICS has commanded the strongest identity and value position.
The company will execute a public launch of its new corporate identity at the European Respiratory Society (ERS) Annual Congress 2012 in Vienna, Austria. The ERS, which takes place Sept. 1-5 this year, is the biggest international gathering of respiratory professionals, who come together to learn about the most current scientific developments, cardiorespiratory technology innovations, newly released products, clinical practice, and patient care.
MGC Diagnostics is a worldwide medical technology company dedicated to cardiorespiratory health solutions. The company is engaged in developing, manufacturing, and marketing noninvasive diagnostics systems. MGC Diagnostics’ portfolio of products provides solutions for disease detection, integrated care, and wellness across the spectrum of cardiorespiratory healthcare. The company’s products are sold internationally through distributors and in the U.S. through a direct sales force, which targets heart and lung specialists in hospitals, university-based medical centers, medical clinics, physician offices, pharmaceutical companies, medical device manufacturers, and clinical research organizations.
About QualityStocks
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.net
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
